Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research
Published in: Breast Cancer Research 5/2009

Open Access 01-10-2009 | Research article

BU-32: a novel proteasome inhibitor for breast cancer

Authors: Joseph K Agyin, Bindu Santhamma, Hareesh B Nair, Sudipa S Roy, Rajeshwar R Tekmal

Published in: Breast Cancer Research | Issue 5/2009

Login to get access

Abstract

Introduction

Proteasome inhibition provides an attractive approach to cancer therapy and may have application in the treatment of breast cancer. However, results of recent clinical trials to evaluate the effect of the proteasome inhibitor Bortezomib (Velcade®, also called PS-341) in metastatic breast cancer patients have shown limited activity when used as a single agent. This underscores the need to find new and more efficacious proteasome inhibitors. In this study, we evaluate the efficacy of the novel proteasome inhibitor BU-32 (NSC D750499-S) using in vitro and in vivo breast cancer models.

Methods

We have recently synthesized a novel proteasome inhibitor (BU-32) and tested its growth inhibitory effects in different breast cancer cells including MCF-7, MDA-MB-231, and SKBR3 by in vitro cytotoxicity and proteasomal inhibition assays. The apoptotic potential of BU32 was tested using flow cytometry and analyzing cell cycle regulatory proteins. In vivo tumor xenograft studies for solid tumor as well as tumor metastasis were conducted using MDA-MB-231-GFP cells.

Results

We report for the first time that BU-32 exhibits strong cytotoxicity in a panel of cell lines: MDA-MB-231 (IC50 = 5.8 nM), SKBR3 (IC50 = 5.7 nM) and MCF-7 cells (IC50 = 5.8 nM). It downregulates a wide array of angiogenic marker genes and upregulates apoptotic markers, including Bid and Bax. Incubation of MDA-MB-231 cells with BU-32 results in the accumulation of cell cycle inhibitor proteins p21 and p27 and stabilization of the tumor suppressor protein p53. Studies in in vivo solid tumor and metastasis models show significant effect with a 0.06 mg/kg dose of BU-32 and marked reduction in tumor burden in the skeleton.

Conclusions

We have shown that BU-32 is effective in cultured breast cancer cells and in breast cancer xenografts. The results suggest its potential benefit in breast cancer treatment.
Appendix
Available only for authorised users
Literature
1.
Ciechanover A: Proteolysis: from the lysosome to ubiquitin and the proteasome. Nat Rev Mol Cell Biol. 2005, 6: 79-87. 10.1038/nrm1552.CrossRefPubMed
2.
Dalton WS: The proteasome. Semin Oncol. 2004, 31: 3-9. 10.1053/j.seminoncol.2004.10.012. discussion 33.CrossRefPubMed
3.
Kisselev AF, Goldberg AL: Proteasome inhibitors: from research tools to drug candidates. Chem Biol. 2001, 8: 739-758. 10.1016/S1074-5521(01)00056-4.CrossRefPubMed
4.
Groll M, Berkers CR, Ploegh HL, Ovaa H: Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome. Structure. 2006, 14: 451-456. 10.1016/j.str.2005.11.019.CrossRefPubMed
5.
Orlowski M, Cardozo C, Michaud C: Evidence for the presence of five distinct proteolytic components in the pituitary multicatalytic proteinase complex. Properties of two components cleaving bonds on the carboxyl side of branched chain and small neutral amino acids. Biochemistry. 1993, 32: 1563-1572. 10.1021/bi00057a022.CrossRefPubMed
6.
Kisselev AF, Goldberg AL: Monitoring activity and inhibition of 26S proteasomes with fluorogenic peptide substrates. Methods Enzymol. 2005, 398: 364-378. 10.1016/S0076-6879(05)98030-0.CrossRefPubMed
7.
Lowe J, Stock D, Jap B, Zwickl P, Baumeister W, Huber R: Crystal structure of the 20S proteasome from the archaeon T. acidophilum at 3.4 A resolution. Science. 1995, 268: 533-539. 10.1126/science.7725097.CrossRefPubMed
8.
Brannigan JA, Dodson G, Duggleby HJ, Moody PC, Smith JL, Tomchick DR, Murzin AG: A protein catalytic framework with an N-terminal nucleophile is capable of self-activation. Nature. 1995, 378: 416-419. 10.1038/378416a0.CrossRefPubMed
9.
Groll M, Huber R: Inhibitors of the eukaryotic 20S proteasome core particle: a structural approach. Biochim Biophys Acta. 2004, 1695: 33-44. 10.1016/j.bbamcr.2004.09.025.CrossRefPubMed
10.
Codony-Servat J, Tapia MA, Bosch M, Oliva C, Domingo-Domenech J, Mellado B, Rolfe M, Ross JS, Gascon P, Rovira A, Albanell J: Differential cellular and molecular effects of bortezomib, a proteasome inhibitor, in human breast cancer cells. Mol Cancer Ther. 2006, 5: 665-675. 10.1158/1535-7163.MCT-05-0147.CrossRefPubMed
11.
An B, Goldfarb RH, Siman R, Dou QP: Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed, but not normal, human fibroblasts. Cell Death Differ. 1998, 5: 1062-1075. 10.1038/sj.cdd.4400436.CrossRefPubMed
12.
Lopes UG, Erhardt P, Yao R, Cooper GM: p53-dependent induction of apoptosis by proteasome inhibitors. J Biol Chem. 1997, 272: 12893-12896. 10.1074/jbc.272.20.12893.CrossRefPubMed
13.
Frankel A, Man S, Elliott P, Adams J, Kerbel RS: Lack of multicellular drug resistance observed in human ovarian and prostate carcinoma treated with the proteasome inhibitor PS-341. Clin Cancer Res. 2000, 6: 3719-3728.PubMed
14.
Adams J, Palombella VJ, Sausville EA, Johnson J, Destree A, Lazarus DD, Maas J, Pien CS, Prakash S, Elliott PJ: Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res. 1999, 59: 2615-2622.PubMed
15.
Hideshima T, Richardson P, Chauhan D, Palombella VJ, Elliott PJ, Adams J, Anderson KC: The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res. 2001, 61: 3071-3076.PubMed
16.
Adams J: The proteasome: a suitable antineoplastic target. Nat Rev Cancer. 2004, 4: 349-360. 10.1038/nrc1361.CrossRefPubMed
17.
Crawford LJ, Walker B, Ovaa H, Chauhan D, Anderson KC, Morris TC, Irvine AE: Comparative selectivity and specificity of the proteasome inhibitors BzLLLCOCHO, PS-341, and MG-132. Cancer Res. 2006, 66: 6379-6386. 10.1158/0008-5472.CAN-06-0605.CrossRefPubMed
18.
Ludwig H, Khayat D, Giaccone G, Facon T: Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies. Cancer. 2005, 104: 1794-1807. 10.1002/cncr.21414.CrossRefPubMed
19.
Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D, San-Miguel JF, Bladé J, Boccadoro M, Cavenagh J, Dalton WS, Boral AL, Esseltine DL, Porter JB, Schenkein D, Anderson KC: Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005, 352: 2487-2498. 10.1056/NEJMoa043445.CrossRefPubMed
20.
Teicher BA, Ara G, Herbst R, Palombella VJ, Adams J: The proteasome inhibitor PS-341 in cancer therapy. Clin Cancer Res. 1999, 5: 2638-2645.PubMed
21.
Goy A, Younes A, McLaughlin P, Pro B, Romaguera JE, Hagemeister F, Fayad L, Dang NH, Samaniego F, Wang M, Broglio K, Samuels B, Gilles F, Sarris AH, Hart S, Trehu E, Schenkein D, Cabanillas F, Rodriguez AM: Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol. 2005, 23: 667-675. 10.1200/JCO.2005.03.108.CrossRefPubMed
22.
O'Connor OA, Wright J, Moskowitz C, Muzzy J, MacGregor-Cortelli B, Stubblefield M, Straus D, Portlock C, Hamlin P, Choi E, Dumetrescu O, Esseltine D, Trehu E, Adams J, Schenkein D, Zelenetz AD: Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol. 2005, 23: 676-684. 10.1200/JCO.2005.02.050.CrossRefPubMed
23.
Rajkumar SV, Richardson PG, Hideshima T, Anderson KC: Proteasome inhibition as a novel therapeutic target in human cancer. J Clin Oncol. 2005, 23: 630-639. 10.1200/JCO.2005.11.030.CrossRefPubMed
24.
Orlowski RZ, Dees EC: The role of the ubiquitination-proteasome pathway in breast cancer: applying drugs that affect the ubiquitin-proteasome pathway to the therapy of breast cancer. Breast Cancer Res. 2003, 5: 1-7. 10.1186/bcr460.CrossRefPubMed
25.
Cardoso F, Ross JS, Picart MJ, Sotiriou C, Durbecq V: Targeting the ubiquitin-proteasome pathway in breast cancer. Clin Breast Cancer. 2004, 5: 148-157. 10.3816/CBC.2004.n.020.CrossRefPubMed
26.
Davis NB, Taber DA, Ansari RH, Ryan CW, George C, Vokes EE, Vogelzang NJ, Stadler WM: Phase II trial of PS-341 in patients with renal cell cancer: a University of Chicago phase II consortium study. J Clin Oncol. 2004, 22: 115-119. 10.1200/JCO.2004.07.165.CrossRefPubMed
27.
Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, Rajkumar SV, Srkalovic G, Alsina M, Alexanian R, Siegel D, Orlowski RZ, Kuter D, Limentani SA, Lee S, Hideshima T, Esseltine DL, Kauffman M, Adams J, Schenkein DP, Anderson KC: A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003, 348: 2609-2617. 10.1056/NEJMoa030288.CrossRefPubMed
28.
Orlowski RZ, Stinchcombe TE, Mitchell BS, Shea TC, Baldwin AS, Stahl S, Adams J, Esseltine DL, Elliott PJ, Pien CS, Guerciolini R, Anderson JK, Depcik-Smith ND, Bhagat R, Lehman MJ, Novick SC, O'Connor OA, Soignet SL: Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol. 2002, 20: 4420-4427. 10.1200/JCO.2002.01.133.CrossRefPubMed
29.
Papandreou CN, Daliani DD, Nix D, Yang H, Madden T, Wang X, Pien CS, Millikan RE, Tu SM, Pagliaro L, Kim J, Adams J, Elliott P, Esseltine D, Petrusich A, Dieringer P, Perez C, Logothetis CJ: Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol. 2004, 22: 2108-2121. 10.1200/JCO.2004.02.106.CrossRefPubMed
30.
Loidl G, Groll M, Musiol HJ, Ditzel L, Huber R, Moroder L: Bifunctional inhibitors of the trypsin-like activity of eukaryotic proteasomes. Chem Biol. 1999, 6: 197-204. 10.1016/S1074-5521(99)80036-2.CrossRefPubMed
31.
Loidl G, Groll M, Musiol HJ, Huber R, Moroder L: Bivalency as a principle for proteasome inhibition. Proc Natl Acad Sci USA. 1999, 96: 5418-5422. 10.1073/pnas.96.10.5418.CrossRefPubMedPubMedCentral
32.
Loidl G, Musiol HJ, Groll M, Huber R, Moroder L: Synthesis of bivalent inhibitors of eucaryotic proteasomes. J Pept Sci. 2000, 6: 36-46. 10.1002/(SICI)1099-1387(200001)6:1<36::AID-PSC232>3.0.CO;2-2.CrossRefPubMed
33.
Chauhan D, Singh A, Brahmandam M, Podar K, Hideshima T, Richardson P, Munshi N, Palladino MA, Anderson KC: Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma. Blood. 2008, 111: 1654-1664. 10.1182/blood-2007-08-105601.CrossRefPubMedPubMedCentral
34.
Arendt CS, Hochstrasser M: Identification of the yeast 20S proteasome catalytic centers and subunit interactions required for active-site formation. Proc Natl Acad Sci USA. 1997, 94: 7156-7161. 10.1073/pnas.94.14.7156.CrossRefPubMedPubMedCentral
35.
Heinemeyer W, Fischer M, Krimmer T, Stachon U, Wolf DH: The active sites of the eukaryotic 20 S proteasome and their involvement in subunit precursor processing. J Biol Chem. 1997, 272: 25200-25209. 10.1074/jbc.272.40.25200.CrossRefPubMed
36.
Kisselev AF, Callard A, Goldberg AL: Importance of the different proteolytic sites of the proteasome and the efficacy of inhibitors varies with the protein substrate. J Biol Chem. 2006, 281: 8582-8590. 10.1074/jbc.M509043200.CrossRefPubMed
37.
Chauhan D, Hideshima T, Anderson KC: Proteasome inhibition in multiple myeloma: therapeutic implication. Annu Rev Pharmacol Toxicol. 2005, 45: 465-476. 10.1146/annurev.pharmtox.45.120403.100037.CrossRefPubMed
38.
Berkers CR, Verdoes M, Lichtman E, Fiebiger E, Kessler BM, Anderson KC, Ploegh HL, Ovaa H, Galardy PJ: Activity probe for in vivo profiling of the specificity of proteasome inhibitor bortezomib. Nat Methods. 2005, 2: 357-362. 10.1038/nmeth759.CrossRefPubMed
39.
Breitschopf K, Zeiher AM, Dimmeler S: Ubiquitin-mediated degradation of the proapoptotic active form of bid. A functional consequence on apoptosis induction. J Biol Chem. 2000, 275: 21648-21652. 10.1074/jbc.M001083200.CrossRefPubMed
40.
Hideshima T, Mitsiades C, Akiyama M, Hayashi T, Chauhan D, Richardson P, Schlossman R, Podar K, Munshi NC, Mitsiades N, Anderson KC: Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood. 2003, 101: 1530-1534. 10.1182/blood-2002-08-2543.CrossRefPubMed
41.
Yang Y, Ikezoe T, Saito T, Kobayashi M, Koeffler HP, Taguchi H: Proteasome inhibitor PS-341 induces growth arrest and apoptosis of non-small cell lung cancer cells via the JNK/c-Jun/AP-1 signaling. Cancer Sci. 2004, 95: 176-180. 10.1111/j.1349-7006.2004.tb03200.x.CrossRefPubMed
42.
Shah SA, Potter MW, McDade TP, Ricciardi R, Perugini RA, Elliott PJ, Adams J, Callery MP: 26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer. J Cell Biochem. 2001, 82: 110-122. 10.1002/jcb.1150.CrossRefPubMed
43.
Williams SA, McConkey DJ: The proteasome inhibitor bortezomib stabilizes a novel active form of p53 in human LNCaP-Pro5 prostate cancer cells. Cancer Res. 2003, 63: 7338-7344.PubMed
44.
Li B, Dou QP: Bax degradation by the ubiquitin/proteasome-dependent pathway: involvement in tumor survival and progression. Proc Natl Acad Sci USA. 2000, 97: 3850-3855. 10.1073/pnas.070047997.CrossRefPubMedPubMedCentral
45.
Boccadoro M, Morgan G, Cavenagh J: Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy. Cancer Cell Int. 2005, 5: 18-10.1186/1475-2867-5-18.CrossRefPubMedPubMedCentral
46.
Demo SD, Kirk CJ, Aujay MA, Buchholz TJ, Dajee M, Ho MN, Jiang J, Laidig GJ, Lewis ER, Parlati F, Shenk KD, Smyth MS, Sun CM, Vallone MK, Woo TM, Molineaux CJ, Bennett MK: Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. Cancer Res. 2007, 67: 6383-6391. 10.1158/0008-5472.CAN-06-4086.CrossRefPubMed
47.
Ling YH, Liebes L, Jiang JD, Holland JF, Elliott PJ, Adams J, Muggia FM, Perez-Soler R: Mechanisms of proteasome inhibitor PS-341-induced G(2)-M-phase arrest and apoptosis in human non-small cell lung cancer cell lines. Clin Cancer Res. 2003, 9: 1145-1154.PubMed
48.
Kuerbitz SJ, Plunkett BS, Walsh WV, Kastan MB: Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci USA. 1992, 89: 7491-7495. 10.1073/pnas.89.16.7491.CrossRefPubMedPubMedCentral
49.
50.
MacLaren AP, Chapman RS, Wyllie AH, Watson CJ: p53-dependent apoptosis induced by proteasome inhibition in mammary epithelial cells. Cell Death Differ. 2001, 8: 210-218. 10.1038/sj.cdd.4400801.CrossRefPubMed
51.
Cusack JC, Liu R, Houston M, Abendroth K, Elliott PJ, Adams J, Baldwin AS: Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition. Cancer Res. 2001, 61: 3535-3540.PubMed
52.
Hideshima T, Chauhan D, Richardson P, Mitsiades C, Mitsiades N, Hayashi T, Munshi N, Dang L, Castro A, Palombella V, Adams J, Anderson KC: NF-κB as a therapeutic target in multiple myeloma. J Biol Chem. 2002, 277: 16639-16647. 10.1074/jbc.M200360200.CrossRefPubMed
53.
McConkey DJ: Bortezomib paradigm shift in myeloma. Blood. 2009, 114: 931-932. 10.1182/blood-2009-06-223230.CrossRefPubMed
54.
Hideshima T, Ikeda H, Chauhan D, Okawa Y, Raje N, Podar K, Mitsiades C, Munshi NC, Richardson PG, Carrasco RD, Anderson KC: Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells. Blood. 2009, 114: 1046-1052. 10.1182/blood-2009-01-199604.CrossRefPubMedPubMedCentral
55.
Seon BK: Expression of endoglin (CD105) in tumor blood vessels. Int J Cancer. 2002, 99: 310-311. 10.1002/ijc.10378.CrossRefPubMed
56.
Roccaro AM, Hideshima T, Raje N, Kumar S, Ishitsuka K, Yasui H, Shiraishi N, Ribatti D, Nico B, Vacca A, Dammacco F, Richardson PG, Anderson KC: Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells. Cancer Res. 2006, 66: 184-191. 10.1158/0008-5472.CAN-05-1195.CrossRefPubMed
57.
Folkman J, Browder T, Palmblad J: Angiogenesis research: guidelines for translation to clinical application. Thromb Haemost. 2001, 86: 23-33.PubMed
58.
Ortega N, Hutchings H, Plouet J: Signal relays in the VEGF system. Front Biosci. 1999, 4: D141-D152. 10.2741/Ortéga.PubMed
59.
Yang S, Toy K, Ingle G, Zlot C, Williams PM, Fuh G, Li B, de Vos A, Gerritsen ME: Vascular endothelial growth factor-induced genes in human umbilical vein endothelial cells: relative roles of KDR and Flt-1 receptors. Arterioscler Thromb Vasc Biol. 2002, 22: 1797-1803. 10.1161/01.ATV.0000038995.31179.24.CrossRefPubMed
60.
Gille H, Kowalski J, Li B, LeCouter J, Moffat B, Zioncheck TF, Pelletier N, Ferrara N: Analysis of biological effects and signaling properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2). A reassessment using novel receptor-specific vascular endothelial growth factor mutants. J Biol Chem. 2001, 276: 3222-3230. 10.1074/jbc.M002016200.CrossRefPubMed
Metadata
Title
BU-32: a novel proteasome inhibitor for breast cancer
Authors
Joseph K Agyin
Bindu Santhamma
Hareesh B Nair
Sudipa S Roy
Rajeshwar R Tekmal
Publication date
01-10-2009
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 5/2009
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr2411

Other articles of this Issue 5/2009

Breast Cancer Research 5/2009 Go to the issue

Editorial

Development of 'synthetic lethal' strategies to target BRCA1-deficient breast cancer

Research article

Steroid Receptor RNA Activator Protein (SRAP): a potential new prognostic marker for estrogen receptor-positive/node-negative/younger breast cancer patients

Research article

Estrogen and progesterone receptors have distinct roles in the establishment of the hyperplastic phenotype in PR-A transgenic mice

Editorial

Notch versus the proteasome: what is the target of γ-secretase inhibitor-I?

Commentary

Physical activity and breast cancer survival

Research article

Therapeutic targeting of the focal adhesion complex prevents oncogenic TGF-β signaling and metastasis
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits